Monthly GLP-1 Injections Move Closer to Clinical Reality as Pfizer and Amgen Advance Trials
The main method in GLP-1 treatment focuses on weekly subcutaneous injections. This schedule balances the drug’s half-life with what is convenient for patients. In response, manufacturers are now exploring new formulations. These new designs provide therapeutic activity for a full month.
Both companies shared new clinical data at recent scientific conferences. This report is a significant step toward longer-interval GLP-1 treatment. The challenge of monthly dosing is still considerable. Approved GLP-1 receptor agonists lose their effectiveness after about seven days.
The body metabolizes these active ingredients quickly. Pfizer’s experimental drug, berobenatide, tackles this issue. It binds steadily to albumin, a protein in the plasma. This binding protects the drug molecule from being broken down by enzymes.
As a result, this action prolongs the drug’s effective half-life. Interim results from Pfizer’s ongoing mid-stage trial showed strong efficacy. Researchers presented these results at the American Diabetes Association’s annual conference. The data revealed an average weight loss of 12.3 percent.
This weight loss took place over 28 weeks in patients who do not have diabetes. In addition, a parallel trial showed improvements in blood sugar control. This second mid-stage study looked at patients with type 2 diabetes. Participants started with weekly injections and gradually received lower doses.
They then switched to monthly administration. This dosing approach helps limit gastrointestinal side effects when starting treatment. The full trial will last for 64 weeks. Researchers also noted that berobenatide has a specific advantage for patient comfort.
This advantage relates to how the GLP-1 receptor signals through two different pathways inside cells. Berobenatide activates only one of these pathways. In contrast, regular GLP-1 agonists engage both pathways at once.
This targeted signaling profile explains the favorable side effect profile. More data is needed to confirm this result in larger groups. Meanwhile, Amgen’s monthly candidate, MariTide, uses a different engineering strategy. This drug employs an antibody scaffold to extend its time in the body.
In addition to GLP-1 receptor activity, MariTide’s antibody also targets the GIP receptor. The drug blocks this receptor instead of activating it. This action sets MariTide apart from tirzepatide, which activates the GIP receptor. Still, both methods lead to considerable weight loss.
Researchers admit that they do not fully understand the exact weight loss mechanism. A mid-stage trial involving nearly 600 adults tested MariTide. The drug resulted in an average weight loss of up to 20 percent. This significant loss occurred over 52 weeks of treatment.
MariTide is currently in late-stage clinical testing. Amgen is also investigating whether doctors can extend the dosing interval even further. They are looking into possible dosing schedules every two or three months. Furthermore, reducing how often patients need injections could help with long-term adherence.
This is especially helpful for patients who have trouble with weekly schedules. Travel, illness, or other commitments can often disrupt these routines. Doctors point out that having fewer injections does not automatically boost compliance. Therefore, they need to closely consider each patient’s needs.
Monthly dosing decreases the number of reminders to take medication. Some patients depend on these regular reminders to stay on track. As a result, doctors will likely personalize decisions about dosing schedules. These choices will reflect patient comfort and their history of adherence.
